News

Stocktwits on MSN22h
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled
Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the ...
PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial
PDS Biotechnology Corporation (NASDAQ:PDSB) unveiled compelling new data on its Versamune HPV (PDS0101) immunotherapy at the ...
Merus updates on Petosemtamab+Pembrolizumab data in HNSCC
N.V. “announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be ...
Medscape15d
Pembrolizumab for Advanced Melanoma: Is It Worth It?
Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an ...
Is TIGIT Still A Valid Target In Lung Cancer Patients? Arcus May Be Next To Fail
Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...
Merus Stock Climbs on Positive Trial Results
Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer. The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the ...
Rakuten Medical Announces Trial in Progress Poster Presentation at ASCO 2025 and Enrollment Expansion to Taiwan for Global Phase 3 ASP-1929-381
Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...
Oncology Nurse Advisor5d
Data Confirm Pembrolizumab Regimens as Standard for Recurrent/Metastatic HNSCC
Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.
Medscape18d
Perioperative Pembrolizumab’s Strong Results for HNSCC Raise Questions
Adding pembrolizumab to standard-of-care treatment improved event-free survival (EFS) in locally advanced head and neck squamous cell carcinoma (HNSCC), according to new results of the KEYNOTE-689 ...
Nasdaq1mon
Merus N.V. Announces Interim Clinical Data for Petosemtamab with Pembrolizumab in PD-L1+ r/m HNSCC to be Presented at 2025 ASCO® Annual Meeting
Merus N.V. announced that an abstract for petosemtamab combined with pembrolizumab as a first-line treatment for PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC ...
The American Journal of Managed Care27d
Pembrolizumab Before, After Surgery Improves Head and Neck Cancer Outcomes: Ravindra Uppaluri, MD, PhD
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and ...